Lupus clinical development: Will belimumab's approval catalyse a new paradigm for SLE drug development?

Expert Opinion on Biological Therapy

Volumn 14, Issue 4, 2014, Pages 491-501

  Runkel, Laura ^a   Stacey, Jennifer ^b  

^a Trialtrove Citeline Autoimmune and Inflammation Disease   (United States)

^b Trialtrove Citeline Autoimmune and Inflammation Disease   (United Kingdom)

Author keywords

BAFF; Belimumab; BLyS; Clinical trial; Lupus; Pharmacotherapy; Systemic lupus erythematosus

Indexed keywords

ABATACEPT; ALITRETINOIN; ANIFROLUMAB; ARSENIC TRIOXIDE; ATACICEPT; BELIMUMAB; BLISIBIMOD; CLARITHROMYCIN; CLOFAZIMINE; EARLY PREGNANCY FACTOR; EPRATUZUMAB; FORIGERIMOD; HYDROXYCHLOROQUINE; LAQUINIMOD; MILATUZUMAB; MYCOPHENOLIC ACID; RAPAMYCIN; RIFABUTIN; RONTALIZUMAB; SALBUTAMOL; SIFALIMUMAB; SIRUKUMAB; TABALUMAB; VELTUZUMAB; VOCLOSPORIN;

B LYMPHOCYTE; DRUG APPROVAL; DRUG INDUSTRY; DRUG INFORMATION; DRUG SAFETY; DRUG TREATMENT FAILURE; HUMAN; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; TARGET CELL;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; CLINICAL TRIALS AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; DRUG INDUSTRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; TREATMENT OUTCOME;

EID: 84896129828     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2014.884065     Document Type: Review

References (36)

1. Schneider P, MacKay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth. J Exp Med 1999;189(11):1747-56
2. Fairfax K, Mackay IR, Mackay F. BAFF/BLyS inhibitors: a new prospect for treatment of systemic lupus erythematosus. IUBMB Life 2012;64(7):595-602 . Review of BlyS pathway and its relevance to SLE.
3. Furie R, Stohl W, Ginzler EM, et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10:R109
4. Wallace DJ, Stohl W, Furie RA, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61(9):1168-78
5. Furie RA, Petri MA, Wallace DJ, et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009;61(9):1143-51 .
6. Stohl W, Hilbert DM. The discovery and development of belimumab: the anti-BLyS-lupus connection. Nat Biotechnol 2012;30(1):69-77 .
7. Day ES, Cachero TG, Qian F, et al. Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 2005;44(6):1919-31
8. Baker KP, Edwards BM, Main SH, et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003;48:3253-65
9. Genovese MC, Lee E, Satterwhite J, et al. A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate. Ann Rheum Dis 2013;72(9):1453-60
10. Manzi S, Sa'nchez-Guerrero J, Merrill JT, et al. Effects of belimumab, a B lymphocyte stimulator-specific inhibitor, on disease activity across multiple organ domains in patients with systemic lupus erythematosus: combined results from two phase III trials. Ann Rheum Dis 2012;71(11):1833-8
11. Wallace DJ, Kalunian K, Petri MA, et al. Efficacy and safety of epratuzumab in patients with moderate/severe active systemic lupus erythematosus: results from EMBLEM, a phase IIb, randomised, double-blind, placebocontrolled, multicentre study. Ann Rheum Dis 2014;73:183-90.
12. Development of a quantitative PCR method to determine interferon signature metric status in sle patients: distribution and clinical & serological associations in two lupus clinical trials. ACR/ARHP Annual Meeting Publications; 2012. Abstract Supplement available from http://www.rheumatology. org/publications/acr-arhp-annual-meeting. asp
13. Efficacy and safety of atacicept for prevention of flares in patients with moderate to severe systemic lupus erythematosus (SLE): 52-Wk Data (APRIL-SLE Trial). EULAR Annual European Congress of Rheumatology; 2013. Available from: http://www. abstracts2view.com/eular/view.php? nu=EULAR13L-THU0276
14. Blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus. Am Coll Rheumatol 2012;Abstract Supplement available from http://www.rheumatology.org/publications/acr-arhp- annual-meeting.asp
15. Ginzler EM, Wax S, Rajeswaran A. Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial. Arthritis Res Ther 2012;14(1):R33
16. A Phase IIb, multi-center, randomized, double-blind, placebo-controlled, multidose, 24-week study to evaluate the efficacy and safety of atacicept in subjects with systemic lupus erythematosus (SLE). Available from: http://clinicaltrials.gov/ct2/show/NCT01972568
17. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010;62(1):222-33 . Results of the EXPLORER trial.
18. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab study. Arthritis Rheum 2012;64(4):1215-26.
19. Mysler EF, Spindler AJ, Guzman R, et al. Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study. Arthritis Rheum 2013;65(9):2368-79
20. Lauwerys BR, Hachulla E, Spertini F, et al. Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum 2013;65(2):447-56
21. Results of a randomized, placebocontrolled, phase 2a study of sifalimumab, an anti-interferon-alpha monoclonal antibody, administered subcutaneously in subjects with systemic lupus erythematosus. Annual European congress of Rheumatology Publication; 2011. Abstract available from http://www.abstracts2view.com/eular/view.php? nu=EULAR11L-THU0411&terms=
22. Efficacy and safety of rontalizumab (anti-interferon alpha) in sle subjects with restricted immunosuppressant use: results of a randomized, double-blind, placebocontrolled phase 2 study. ACR/ARHP Annual Meeting Publications; 2012. Abstract supplement Available from http://www.rheumatology. org/publications/acr-arhp-annual-meeting.asp
23. Belnoue E, Pihlgren M, McGaha TL, et al. APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells. Blood 2008;111(5):2755-64
24. Roschke V, Sosnovtseva S, Ward CD, et al. BLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseases. J Immunol 2002;169:4314-21
25. Taylor PC, Feldmann M. Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis. Nat Rev Rheumatol 2009;5(10):578-82
26. Merrill JT, Burgoes-Vargas R, Westhoven R, et al. The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010;62(10):3077-87
27. A randomized, double-blind, controlled, phase ii multicenter trial of ctla4ig (abatacept) plus cyclophosphamide vs cyclophosphamide alone in the treatment of lupus nephritis. Available from: http://clinicaltrials.gov/ct2/ show/NCT00774852
28. Wallace DJ, Gordon C, Strand V, et al. Efficacy and safety of epratuzumab in patients with moderate/severe flaring systemic lupus erythematosus: results from two randomized, double-blind, placebocontrolled, multicentre studies (ALLEVIATE) and follow-up. Rheumatology 2013;52(7):1313-22
29. Reddy V, Jayne D, Close D, Isenberg D. B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design. Arthritis Res Ther 2013;15(Suppl 1):S2
30. Van Vollenhoven RF, Parodis I, Levitsky A. Biologics in SLE: towards new approaches. Best Pract Res Clin Rheumatol 2013;27(3):341-9
31. Witt M, Grunke M, Proft F, et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus 2013;22(11):1142-9
32. Crow MK. Type I interferon in organtargeted autoimmune and inflammatory diseases. Arthritis Res Ther 2010;12(Suppl 1):S5
33. Shrivastav M, Niewold TB. Nucleic acid sensors and type I interferon production in systemic lupus erythematosus. Front Immunol 2013;4:319
34. A randomized, double-blind, placebocontrolled, single dose, two-period, crossover study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of amg 811 in subjects with discoid lupus erythematosus. Available from: http://clinicaltrials.gov/show/NCT01164917
35. A Phase 1b, randomized, double-blind, placebo-controlled, multiple dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of amg 811 in subjects with systemic lupus erythematosus with and without glomerulonephritis. Available from: http://clinicaltrials.gov/ct2/ show/NCT00818948
36. First in human study of an anti-ifn gamma monoclonal antibody in healthy volunteers. Available from: http://clinicaltrials.gov/ct2/show/NCT01459562